Vincent M. Chung

B7-H4‒directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors: the Phase 1/2a (BLUESTAR), first-in-human study

B7-H4 is a promising antibody-drug conjugate (ADC) target with high expression in several solid tumors and limited expression in normal tissue. B7-H4 negatively regulates T-cell function, and high expression of B7-H4 is associated with disease progression. AZD8205 (puxitatug samr...

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Camupepimut (ELI-002 7P) drives mutated KRAS (mKRAS)-specific T cell responses that correlated with disease-free survival (DFS) and overall survival (OS) in patients with mKRAS pancreatic adenocarcinoma (PDAC) in the phase 1 AMPLIFY-201 trial. In the phase 2 AMPLIFY-7P trial, pat...